Table 3.
Comparison of pathological characteristics between MMR-deficient and MMR-intact
| Variable |
Intact
(n=77) |
Deficient
(n=23) |
P-value | OR (95% CI) |
|---|---|---|---|---|
| Size tumor (mean± SD) | 36.24±21.33 | 31.17±28.56 | 0.359 | |
| Endometrioid histology | 69 (89.6%) | 22 (95.6%) | 0.374 | 0.392 (0.46-3.31) |
| Lower segment | 20 (26) | 12 (52.2) | 0.018 | 3.11 (1.19-8.16) |
| Myometrium invasion | 39.42 ± 33.11 | 54.13 ± 23.44 | 0.021 | 1.02 (1.01-1.03) |
| Cervical involvement | 10 (13) | 6 (26.1) | 0.191 | 2.37 (0.754-7.42) |
| Ovarian involvement | 11 (14.3) | 2 (8.7) | 0.727 | 0.571 (0.117-2.79) |
| Serosal involvement | 3 (3.9) | 0 (0) | 0.999 | |
| Positive cytology | 1 (1.3) | 1 (4.3) | 0.999 | 3.46 (0.208-54.50) |
| Lymph node involvement | 11 (14.3) | 2 (8.7) | 0.727 | 0.571 (0.117-2.79) |
| LVSI* | 17 (22.1) | 8 (34.8) | 0.217 | 1.88 (0.684-5.18) |
| Omental involvement | 2 (2.6) | 1 (4.3) | 0.548 | 1.71 (0.148-19.70) |
| Stage: | 0.335 | 0.469 (0.98-2.25) | ||
| Early (I+II) | 64 (83.1) | 21 (91.30) | ||
| Late (III+IV) | 13 (16.9) | 2 (8.70) | ||
| Adjuvant therapy | 44 (57.1) | 17 (73.9) | 0.148 | 2.13 (0.755-5.98) |
| Brachytherapy | 38 (49.4) | 14 (60.9) | 0.332 | 1.60 (0.618-4.12) |
| EBRT | 24 (31.2) | 7 (30.4) | 0.947 | 0.966 (0.352-2.65) |
| Chemotherapy | 24 (31.6) | 6 (26.1) | 0.616 | 0.765 (0.268-2.18) |
*LVSI: Lympho-vascular space invasion